---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-071251"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:58:00.229999+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galera Q4/2021 net loss $16.8M; positive Phase 3 ROMAN trial, cash $71M

## Summary
- Net loss of $16.8M ($0.64/sh) in Q4 2021 vs $20.1M ($0.80/sh) in Q4 2020; FY net loss $80.5M ($3.12/sh).
- Phase 3 ROMAN trial of avasopasem met primary endpoint (SOM incidence); plans to meet FDA in 2022 for NDA submission.
- Cash, cash equivalents & short-term investments $71.2M at Dec 31, 2021; expected runway into 2H 2023.
- Topline data from AESOP (esophagitis) and GRECO-1 (lung cancer) both expected in 1H 2022.

## SEC filing metadata
- accession: 0001193125-22-071251
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/0001193125-22-071251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/d310055d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-071251
- JSON: https://secwatch.observer/filing/0001193125-22-071251.json
- Plain text: https://secwatch.observer/filing/0001193125-22-071251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.